Sienna Resources

ENVERIC BIOSCIENCES (NASDAQ: ENVB) STOCK QUOTE

Last Trade: US$0.52 0.0096 1.89
Volume: 150,029
5-Day Change: -0.27%
YTD Change: -60.29%
Market Cap: US$4.000M

LATEST NEWS FROM ENVERIC BIOSCIENCES

US patent includes broad claims for treating brain neurological disorders CAMBRIDGE, Mass. / Jul 10, 2024 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announces the expansion of protection for potential clinical indications for its EB-002 drug candidate... Read More
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s management commentary, recent developments, outlook, and risks. The full research report is available here . Highlights from the report... Read More
EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically associated with psychedelic-based compounds Enveric is advancing pre-clinical development of EB-003 with a pre-IND meeting targeted for early 2025 CAMBRIDGE, Mass. / Jun 25, 2024 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company... Read More
CAMBRIDGE, Mass. / May 30, 2024 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Company will participate in the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6,... Read More
Revealed seven classes of promising novel drug candidates discovered using Enveric’s Psybrary™ and PsyAI™ drug discovery and artificial intelligence (AI) platforms Launched business development campaign that resulted in the execution of seven non-binding term sheets with four strategic partners that upon entering into definitive agreements and performing pursuant to the terms thereof could potentially total up to... Read More
MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic compounds CAMBRIDGE, Mass. / May 14, 2024 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression,... Read More
Biotechnology licensee expected to progress methods targeting breast and other cancers using cannabinoids in combination with chemotherapeutic drugs CAMBRIDGE, Mass. / May 08, 2024 / Business Wire / Enveric Biosciences, Inc (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today... Read More
Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Started IND-enabling preclinical activities for EB-002 and completed important repeat-dose toxicology studies, genotoxicity studies, and key cardiac, respiratory, and CNS safety... Read More
Second biotechnology company to potentially out-license novel compounds from Enveric’s portfolio of assets with possible significant milestone payments and royalties CAMBRIDGE, Mass. / Mar 19, 2024 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression,... Read More
Patents extend compositional protection to proprietary compounds CAMBRIDGE, Mass. / Mar 12, 2024 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that, on March 5, 2024, the United States Patent and... Read More
Potentially significant milestone payments and execution fees if all development and sales criteria are met for all three agreements. CAMBRIDGE, Mass. / Feb 29, 2024 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is... Read More
Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s management commentary, recent developments, outlook, and risks. The full research report is available here . Highlights from the report include: Enveric Sells Cancer-Targeting... Read More
Novel compounds protected under Enveric’s intellectual property portfolio provide potential licensing opportunities and non-dilutive revenue streams. CAMBRIDGE, Mass. / Feb 21, 2024 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction... Read More
Enveric to initiate preclinical development of EB-003 in 2024 in preparation for IND submission CAMBRIDGE, Mass. / Jan 03, 2024 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided an update on data... Read More
CAMBRIDGE, Mass. / Dec 29, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,122,000 shares of the... Read More
Enveric to initiate preclinical development of EB-003 in 2024 in preparation for IND submission CAMBRIDGE, Mass. / Dec 28, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has named EB-003 as... Read More
The ongoing GLP Safety and Toxicology Program of EB-373 is thus far proceeding on time with favorable results CAMBRIDGE, Mass. / Dec 27, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the GLP... Read More
CAMBRIDGE, Mass. / Dec 20, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, announced the company will participate in Biotech Showcase 2024 being held January 8-10, 2024 in San Francisco. Details of the event is as... Read More
Three novel neuroplastic compounds identified with plans to advance one into expedited preclinical development in 2024 CAMBRIDGE, Mass. / Dec 05, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that... Read More
Expands intellectual property portfolio with composition of matter and methods of use claims governing Enveric’s EVM301 Series of drug candidates CAMBRIDGE, Mass. / Nov 29, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction... Read More
Peer-reviewed article describes the creation of a library of novel prodrug derivatives of psilocin from which EB-373 was selected CAMBRIDGE, Mass. / Nov 27, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today... Read More
CAMBRIDGE, Mass. / Nov 24, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the presentation of two posters at the Canadian Chemical Engineering Conference (CSChE 2023) which was held October 29 th... Read More
EVM-301 Series Presented and published leading scientific research describing development and screening methods for non-hallucinogenic, neuroplastogenic drug candidates in Enveric’s EVM301 Series of candidates targeting the treatment of mental health disorders Announced AI-powered drug candidate generation engine surpassed 1000 compounds discovered and analyzed in Psybrary™ portfolio of psychedelic-inspired therapeutic... Read More
Expands its intellectual property portfolio with composition of matter claims governing lead clinical candidate, EB-373, a psilocin prodrug being developed for the treatment of depression and anxiety disorders. CAMBRIDGE, Mass. / Oct 31, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule... Read More
CEO Joseph Tucker, Ph.D., to deliver company presentation and participate in panel discussion CAMBRIDGE, Mass. / Oct 20, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, announced that Joseph Tucker, Ph.D., Chief... Read More
Key preclinical milestone designed to establish safety profile and maximum tolerated dose for anticipated clinical trial of EB-373 CAMBRIDGE, Mass. / Oct 18, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today... Read More
Presentations highlight research involving Enveric’s EVM301 Series of non-hallucinogenic neuroplastogens and the company’s lead product candidate, EB-373 CAMBRIDGE, Mass. / Oct 11, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and... Read More
The Psybrary™ portfolio includes numerous unique, previously unreported molecules, which are protected by Enveric’s expansive and growing intellectual property estate CAMBRIDGE, Mass. / Oct 03, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression,... Read More
Paper co-authored by Enveric researchers describes the discovery of a key cane toad enzyme and its application to the biosynthesis of novel indolethylamine-type drug candidates with potential use in psychiatric medicine CAMBRIDGE, Mass. / Sep 27, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule... Read More
Claims to novel composition of matter and pharmaceutical drug formulations encompass EVM301 Series of drug candidates, targeting various difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations CAMBRIDGE, Mass. / Sep 20, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel... Read More
Poster details advances in screening for non-hallucinogenic, neuroplastogen drug candidates for the treatment of mental health disorders CAMBRIDGE, Mass. / Sep 18, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders,... Read More
Enveric utilizing AI-backed 3D modeling to identify potential non-hallucinogenic, neuroplastic tryptamine derivative NCEs for its EVM301 Series CAMBRIDGE, Mass. / Sep 11, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction... Read More
New patent provides additional composition of matter and methods of use claims for Enveric’s tryptamine-derived prodrugs including EB-373, a new chemical entity psilocin prodrug CAMBRIDGE, Mass. / Sep 05, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of... Read More
CAMBRIDGE, Mass. / Aug 30, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that Joseph Tucker, Ph.D., Chief Executive Officer, will deliver a virtual presentation at the H.C. Wainwright 25 th... Read More
Composition of matter and methods of use claims encompass EB-373, Enveric’s new chemical entity psilocin prodrug being developed for the treatment of anxiety disorder CAMBRIDGE, Mass. / Aug 28, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety,... Read More
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Enveric Biosciences Inc. (NASDAQ: ENVB). The in-depth 23-page initiation report includes detailed information on the Enveric Bioscience ’s business model, services, industry, valuation, management, and risks. The full research report is available... Read More
High purity of manufactured prodrug product allows Enveric and partners to ship EB-373 without being subject to restrictions required for controlled substances CAMBRIDGE, Mass. / Aug 21, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and... Read More
Advanced preclinical pipeline of neuroplastogenic small-molecule therapeutics targeting neuronal atrophy to offer a first-in-class treatment of mental health disorders Secured multiple Notices of Allowance and select issuances from the United States Patent and Trademark Office (the “USPTO”) for composition of matter protections for its lead product candidate, EB-373, and EVM201 and EVM301 Series of compounds Enhanced... Read More
Absorption, distribution, metabolism, and excretion (ADME) and toxicology assays demonstrated rapid conversion of EB-373 to the active metabolite psilocin, consistent with previously reported animal pharmacokinetic (PK) studies CAMBRIDGE, Mass. / Jul 24, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic... Read More
Orally administered EB-373 resulted in dose-dependent increase in psilocin blood concentration in pharmacokinetic (PK) animal studies, correlating to levels expected to be effective based on psilocybin data in humans Outcome of animal studies indicate potential to reduce GI upset and vomiting as well as rapid onset of action and systemic clearance, improving on PK characteristics of psilocybin CAMBRIDGE, Mass. / Jul 17, 2023... Read More
New and enhanced manufacturing process now operational improving yield and purity of material and ease of process Enveric to expand existing manufacturing agreement with CDMO partner for enhanced supply of non-GMP and GMP EB-373 drug substance CAMBRIDGE, Mass. / Jun 26, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel... Read More
CAMBRIDGE, Mass. / Jun 12, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that Joseph Tucker, Ph.D., Chief Executive Officer, will deliver a virtual presentation at the H.C. Wainwright 4th Annual Neuropsychiatry... Read More
CAMBRIDGE, Mass. / Jun 07, 2023 / Business Wire / Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that its research involving the synthesis of small molecule derivatives of psychoactive compounds has been featured in two poster... Read More
New composition of matter claims establish intellectual property for Enveric’s EVM301 Series of novel small molecules designed to promote neuroplasticity without inducing hallucinations. CAMBRIDGE, Mass. / Jun 05, 2023 / Business Wire / Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety,... Read More
CAMBRIDGE, Mass. / May 30, 2023 / Business Wire / Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that research foundational to the development of the Company’s EVM201 Series and EVM301 Series is featured in a poster presentation at... Read More
New composition of matter claims expands intellectual property for Enveric’s EVM201 Series CAMBRIDGE, Mass. / May 24, 2023 / Business Wire / Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has received a Notice of Allowance... Read More
Research highlights the potential of Enveric’s EVM201 Series aimed at developing psilocin prodrugs with altered metabolic profiles that offer superior administration and treatment benefits, but reduce pharmacological exposure CAMBRIDGE, Mass. / May 22, 2023 / Business Wire / Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule... Read More
CAMBRIDGE, Mass. / May 19, 2023 / Business Wire / Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its participation in this year’s 2023 BIO International Convention, which is being held in Boston, MA, June 5-8, 2023. During the... Read More
Intellectual property describes composition of matter claims governing Enveric’s lead clinical candidate, EB-373, which is being developed for the treatment of anxiety disorder CAMBRIDGE, Mass. / May 18, 2023 / Business Wire / Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety,... Read More
Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 Continued to advance pipeline of small molecule therapeutics for the treatment of mental health disorders, including EB-373 for the treatment of anxiety disorder and EVM301 Series Announced termination of proposed spin-off of cannabinoid clinical development pipeline to publicly traded... Read More
Enveric is advancing EB-373, a psilocin prodrug for anxiety disorders and its EVM301 Series of novel non-hallucinatory brain plastogens to treat mental health disorders. CAMBRIDGE, Mass. / May 02, 2023 / Business Wire / Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and... Read More
CEO Joseph Tucker, Ph.D., to discuss Enveric’s pipeline and therapeutic opportunities in fireside chat and “NextGen Psychedelics” panel discussion CAMBRIDGE, Mass. / Apr 10, 2023 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today... Read More
Key Highlights Nominated EB-373 as lead development candidate for the treatment of anxiety disorders EB-373 is a next generation proprietary psilocin prodrug selected from Enveric’s EVM201 Series and developed leveraging the Company’s Psybrary™ drug discovery platform Established Australia-based subsidiary, Enveric Therapeutics Pty. Ltd and identified contract research organization (CRO) Avance Clinical to conduct Phase 1... Read More
EB-373, a proprietary psilocin prodrug, is on track to start its first-in-human clinical trial in the fourth quarter of 2023 CAMBRIDGE, Mass. / Mar 23, 2023 / Business Wire / Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it... Read More
Research details the bioproduction of novel indolethylamine-type drug candidates with potential use in psychiatric medicine Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today new research detailing the first-ever isolation of a novel... Read More
30+ year pharmaceutical industry veteran joins Enveric’s executive team to lead company’s financial and capital markets activities. Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today the appointment of Kevin Coveney, CPA, to the position of... Read More
Accomplished pharmaceutical industry leader brings to Enveric extensive experience in clinical operations, asset strategy and product development Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today the appointment of Lynn Gallant to the... Read More
CEO Joseph Tucker, Ph.D., to deliver company presentation and participate in panel discussion Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that Joseph Tucker, Ph.D., Chief Executive Officer, will present at the Gravitas Securities Inc.... Read More
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that CEO Joseph Tucker, Ph.D., will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City. Details of the presentation are as... Read More
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, announced today that the company will present at the 6 th Annual Neuroscience Forum and the Biotech Showcase™. Both events will be held live and are scheduled to coincide with the 41 st Annual J.P. Morgan... Read More
The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders,... Read More
Enveric Biosciences (NASDAQ: ENVB) (”Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced that Avani Kanubaddi, President & COO of Enveric Biosciences, will participate in A.G.P.’s Virtual Biotech Conference to be held from November 30, 2022 – December 1, 2022. For more... Read More
Enveric Biosciences (NASDAQ: ENVB) (”Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in Wonderland: Miami hosted by Microdose to be held at the Mana Wynwood Convention Center in Miami, FL... Read More
Next Generation Psilocin Prodrug, EB-373, Nominated to Advances to IND-Enabling Studies First Generation EVM101 Program for Cancer Related Distress has been discontinued Enveric Biosciences Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the nomination... Read More
Enveric Biosciences (NASDAQ: ENVB) (”Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the presentation of results from its lead programs at the 6 th International Neurology & Brain Disorders Conference (INBC) to be held on October 24-26, 2022, in Orlando, Florida (... Read More
Enveric Biosciences, Inc . (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has appointed three new independent directors, Michael D. Webb, President and CEO of CXL Ophthalmics, Bevin O'Neil, Chief Strategy Officer of ECRI, and Frank Pasqualone, recently retired Chief Business Officer of... Read More
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 375,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof), priced at a premium to market under... Read More
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has entered into a definitive agreement with an institutional investor for the purchase and sale of 375,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof), in a registered direct... Read More
Enveric Biosciences , Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced the formation of its Scientific Advisory Board (SAB) comprised of science and technology leaders, including globally renowned CNS and mental disorders experts, and chaired by Maurizio Fava, M.D. The SAB will advise... Read More
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares. The reverse stock split will become effective at 4:05 p.m., New York time, on Thursday,... Read More
Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property (IP) advances achieved during the first half of 2022. “The first half of 2022 was foundationally successful for Enveric.... Read More
Enveric Biosciences , Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that Dr. Joseph Tucker , Chief Executive Officer of Enveric, will participate in three upcoming conferences: A.G.P.'s Summer Healthcare Conference Date: June 21 st – 22 nd , 2022 Location: Virtual Gravitas' 3 rd Los... Read More
Enveric Biosciences , Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that Avani Kanubaddi , President and Chief Operating Officer of Enveric, will participate virtually in Microdose's Psychedelic Capital: May 2022 Conference to be held virtually on May 26, 2022 . Mr. Kanubaddi will... Read More
Enveric Biosciences , Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that Dr. Joseph Tucker , Chief Executive Officer of Enveric, will participate virtually in the H.C. Wainwright Global Investment Conference to be held on May 23-26, 2022 . Dr. Tucker's corporate presentation will be... Read More
The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced plans to transfer... Read More
Enveric Biosciences , Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it will host a virtual fireside chat with its Chief Medical Officer, Dr. Bob Dagher , on Tuesday, May 17, 2022 at 10:00 a.m. EDT . Dr. Bob Dagher has over 20 years of clinical research experience within neuroscience... Read More
Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly-designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of Enveric common stock held of record as... Read More
Enveric Biosciences , Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that Dr. Joseph Tucker , Chief Executive Officer of Enveric, will participate in three upcoming investor conferences: Benzinga Psychedelics Capital Conference Date: Tuesday, April 19 th at 11:10 a.m. ET Location:... Read More
Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today reported its financial results for the full year ended December 31, 2021 , and provided a business update. "2021 was a foundational year that set the stage for Enveric to execute on its strategy in the future," said Dr. Joseph Tucker... Read More
Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience company developing next-generation, psychedelic-inspired mental health medicines, announces the filing of a provisional patent application based on new discoveries by the Company. The application describes more than 100 novel individual molecules and, if the broadest claims are allowed, could protect more than 10,000 possible new drug development... Read More
Patent Applications Aim to Expand Opportunities for Novel Therapeutics to Address a Broad Range of Psychiatric and Neurological Disorders Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that the Company's first four Patent Cooperation Treaty (PCT) applications for the... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS